dc.contributor.author |
Leung, Yee Fun |
en |
dc.contributor.author |
Pilkington, Lisa |
en |
dc.contributor.author |
van Rensburg, M |
en |
dc.contributor.author |
Jeon, CY |
en |
dc.contributor.author |
Song, M |
en |
dc.contributor.author |
Arabshahi, HJ |
en |
dc.contributor.author |
De Zoysa, Gayan |
en |
dc.contributor.author |
Sarojini Amma, Vijayalekshmi |
en |
dc.contributor.author |
Denny, William |
en |
dc.contributor.author |
Reynisson, Johannes |
en |
dc.contributor.author |
Barker, David |
en |
dc.date.accessioned |
2017-04-20T02:33:21Z |
en |
dc.date.issued |
2016 |
en |
dc.identifier.citation |
Bioorganic and Medicinal Chemistry 24(5):1142-1154 Mar 2016 |
en |
dc.identifier.issn |
0968-0896 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/32606 |
en |
dc.description.abstract |
Seventy nine derivatives of thieno[2,3-b]quinolines, tetrahydrothieno[2,3-b]quinoline, dihydrocyclopenta[b]thieno[3,2-e]pyridine, cyclohepta[b]thieno[3,2-e]pyridine and hexahydrocycloocta[b]thieno[3,2-e]pyridine were either synthesized or obtained commercially and tested for their antiproliferative activity against HCT116, MDA-MB-468 and MDA-MB-231 human cancer cell lines. The most potent eight compounds were active against all cell lines with IC50 values in the 80-250nM range. In general hexahydrocycloocta[b]thieno[3,2-e]pyridines were most active with increasing activity observed as larger cycloalkyl rings were fused to the pyridine ring. |
en |
dc.relation.ispartofseries |
Bioorganic and Medicinal Chemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Synthesis and cytotoxicity of thieno[2,3-b]quinoline-2-carboxamide and cycloalkyl[b]thieno[3,2-e]pyridine-2-carboxamide derivatives |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/j.bmc.2016.01.047 |
en |
pubs.issue |
5 |
en |
pubs.begin-page |
1142 |
en |
pubs.volume |
24 |
en |
dc.rights.holder |
Copyright: Elsevier |
en |
dc.identifier.pmid |
26853836 |
en |
pubs.end-page |
1154 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
523073 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Chemistry |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
dc.identifier.eissn |
1464-3391 |
en |
pubs.record-created-at-source-date |
2017-07-01 |
en |
pubs.online-publication-date |
2016-01-27 |
en |
pubs.dimensions-id |
26853836 |
en |